References
- McGeown MG. Renal diseases associated with drugs. Iatrogenic diseases, PF D'Arcy, JP Griffin. Oxford University Press, London 1986; 790–810
- Faccini JM. A perspective on the pathology and cytochemistry of renal lesions. Nephrotoxicity assessment and pathogenesis, PH Bach, FW Bonner, JW Bridges, EA Lock. John Wiley, New York 1982; 82–97
- Burry H C, Dieppe PA. Renal function after prolonged consumption of aspirin. Br Med J 1982; 284: 1117–1118
- Hardy J G, Healey J NC, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicycIic acid tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1987; 1: 263–280
- Fischer C, et al. Disposition of 5-aminosalicyclic acid, the active metabolite of sulphasalazine, in man. Eur J Clin Pharmacol 1983; 25: 511–515
- Chasseaud L, et al. The pharmacokinetics and metabolism ofuC-5-aminosalicyclic acid (mesa-lazine) in rats and dogs. SK&F Internal Report. SK&F Research Ltd., The Frythe, Welwyn, HertfordshireEngland 1986
- Norlander B, et al. Pharmacokinetics of 5-amino-salicylic acid enteric-coated tablet and suppository dosage form. Aliment Pharmacol Ther 1989; 3: 333–342
- Diener U, et al. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol 1984; 326: 278–282
- Sansom J, Barnett KC. Keratoconjunctivitis sicca in the dog: a review of 200 cases. J Small Anim Pract 1985; 26: 121–131
- Sansom J, Barnett K C, Long RD. Keratoconjunctivitis sicca in the dog associated with the administration of salicylazosulphapyridine (sulphasalazine). Vet Rec 1985; 116: 391–393
- Barnett K C, Joseph EC. Keratoconjunctivitis sicca in the dog following 5-aminosalicylic acid administration. Hum Toxicol 1987; 6: 377–383